Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study
Top Cited Papers
- 1 February 2001
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 357 (9256), 592-598
- https://doi.org/10.1016/s0140-6736(00)04056-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with LipodystrophyClinical Infectious Diseases, 2000
- Sonographic assessment of regional fat in HIV-1-infected peopleThe Lancet, 2000
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Changes in use of antiretroviral therapy in regions of Europe over timeAIDS, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- Antiretroviral Therapy for HIV Infection in 1997JAMA, 1997
- Body Fat Distribution in Healthy Young and Older MenJournal of Gerontology, 1990
- Studies in the Distribution of Body Fat: I. Effects of Age, Sex, and ObesityJournal of Gerontology, 1989